相关实验视频

Updated: Jan 15, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

对于AR驱动的耐治疗前列腺癌,MECOM功能至关重要

Surendra Gulla¹, Tej Sharma¹, Ephraim Gardner¹

¹University at Buffalo, State University of New York Buffalo, New York United States.

Cancer research

|January 13, 2026

概括

MECOM/EVI1通过协同激活非正规的雄激素受体信号来驱动前列腺癌的进展. MECOM过度表达预测了PARP抑制剂的敏感性,扩大了对割抗性前列腺癌的治疗选择.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

前列腺癌的进展涉及雄激素受体 (AR) 细胞体重编程.
阴道抗性前列腺癌 (CRPC) 经常使用对抗AR信号抑制剂 (ARSI) 的非正规AR信号.

研究的目的:

为了确定参与CRPC非正规AR信号的因素.
研究MECOM/EVI1在前列腺癌中的作用.
探索MECOM/EVI1作为PARP抑制剂治疗的预测生物标志物.

主要方法:

确定了EVI1作为AR招募的协同激活剂.
分析了CRPC和耐酶胺CRPC中的MECOM表达.
在前列腺癌细胞中减少MECOM,以评估对增殖,生存和超级增强剂 (SE) 的影响.
评估了MECOM过度表达细胞对PARP抑制剂的敏感性.

主要成果:

在CRPC和抗酶胺的CRPC中,MECOM仅过度表达,与AR相互作用.
MECOM 枯竭减少了繁殖,改变了生存途径,减少了SE,增加了亡.
过度表达MECOM/EVI1的细胞对PARP抑制剂表现出敏感性,无论DNA损伤反应或HRR基因突变状态如何.

结论:

EVI1在前列腺癌的AR重编程染色质景观中的细胞存活中发挥着关键作用.
过度表达MECOM是一种潜在的生物标志物,可以扩大PARP抑制剂的使用范围,超出HRR突变癌症.

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...